基本信息
浏览量:259
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Dr. Kantarjian has received several prestigious honors and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013),the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America’s Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014) and the ASCO David A. Karnofsky Memorial Award for lifelong contributions to leukemia research and patient care (2023).
Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 2,000 peer-reviewed publications.
Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 2,000 peer-reviewed publications.
研究兴趣
论文共 5859 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer (2024)
Clinical Lymphoma Myeloma and Leukemiano. 7 (2024): 427-432
Journal of the National Comprehensive Cancer Network : JNCCNno. 1 (2024)
Clinical Lymphoma Myeloma and Leukemia (2024)
INTERNATIONAL JOURNAL OF HEMATOLOGY (2024)
Leukemiano. 5 (2024): 1-4
LEUKEMIA & LYMPHOMApp.1-10, (2024)
Blood Neoplasiapp.100008, (2024)
Leukemiano. 5 (2024): 1-4
BLOODno. 5 (2024): 417-421
加载更多
作者统计
#Papers: 5912
#Citation: 286497
H-Index: 228
G-Index: 419
Sociability: 9
Diversity: 3
Activity: 724
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn